Ferguson, M., Schwarz, T. F., Núñez, S. A., Rodriguez-Garcia, J., Mital, M., Zala, C., . . . Hulstrøm, V. (2025). Immune persistence and safety of the AS01-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Citación estilo ChicagoFerguson, Murdo, et al. Immune Persistence and Safety of the AS01-adjuvanted Respiratory Syncytial Virus Prefusion F Protein-based Vaccine in Adults 50-59 years of Age, Including At-increased-risk Adults: A Randomized Controlled Trial. 2025.
Cita MLAFerguson, Murdo, et al. Immune Persistence and Safety of the AS01-adjuvanted Respiratory Syncytial Virus Prefusion F Protein-based Vaccine in Adults 50-59 years of Age, Including At-increased-risk Adults: A Randomized Controlled Trial. 2025.